Literature DB >> 30736175

Somatostatin receptor pathophysiology in the neuroendocrine system.

Manuela Albertelli1, Marica Arvigo1, Mara Boschetti1,2, Diego Ferone1,2, Federico Gatto1, Francesco Minuto1,2,3.   

Abstract

The actions of somatostatin (SRIF) are mediated by specific G protein-coupled receptors, named SRIF receptor (SSTR) subtypes 1, 2, 3 and 5. SRIF binding to SSTR activates a series of second messenger systems, resulting in the inhibition of calcium channels and adenylate cyclase activity, ultimately leading to inhibition of hormone secretion, while stimulation of other second messengers, such as phosphotyrosine phosphatases play a role in the control of cell growth. The SSTR and dopamine receptor families share a 30% sequence homology and appear to be structurally related. The knowledge on the pathophysiology of these two families of G protein-coupled receptors in neuroendocrine tumors has progressively increased due to the new insights in receptor dimerization, internalization and trafficking. Depending on the expression of different SSTRs in tissues, their combinations and interactions affect the functionality of the subtypes expressed and the influence of the microenvironment, the response to ligands and, by consequence, the response to treatment can be very different.

Entities:  

Keywords:  NET; pituitary adenomas; receptor dimerization; receptor signaling; somatostatin; somatostatin analogs; somatostatin receptors

Year:  2013        PMID: 30736175     DOI: 10.1586/eem.13.7

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  2 in total

1.  Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic and Immunohistochemical Study with Focus on Novel Markers (Sst2-Sst5).

Authors:  Frediano Inzani; Angela Santoro; Giuseppe Angelico; Angela Feraco; Saveria Spadola; Damiano Arciuolo; Michele Valente; Angela Carlino; Alessia Piermattei; Giulia Scaglione; Giovanni Scambia; Guido Rindi; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2020-05-12       Impact factor: 6.639

2.  Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.

Authors:  Rosario Pivonello; Pamela N Munster; Massimo Terzolo; Rosario Ferrigno; Chiara Simeoli; Soraya Puglisi; Utsav Bali; Andreas G Moraitis
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-04       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.